SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis
(ASX: PXS; Nasdaq: PXSL) today announced the appointment of IDIS Limited to
manage and provide eligible patients worldwide with access to Bronchitol
through a Named Patient Program.
The program will allow patients who are unable to participate in current
Pharmaxis clinical trials but who are considered by their physician to be
suffering from a clinical condition for which no satisfactory authorised
alternative exists, to receive access to Bronchitol on a named patient basis.
The program will establish a common approach to the use and distribution
of Bronchitol and the eligibility of patients.
"IDIS is a partner of choice for major global pharmaceutical companies in
providing ethical named patient access to medicines in countries where the
product is yet to be authorised," said Pharmaxis CEO Alan Robertson.
"Bronchitol will be made available to people with a chronically or
seriously debilitating, or life threatening condition who cannot be treated
satisfactorily by an authorized medicine.
"IDIS manages Named Patient Programs in over 100 countries, and is
recognised for its rigorous capture of pharmacovigilance information and
quality doctor education programs.
"We are pleased to be able to offer the option of Bronchitol to physicians
with patients in urgent need," said Dr Robertson.
Bronchitol is in final clinical trials for the treatment of the chronic
lung conditions cystic fibrosis and bronchiectasis. The U.S. Food and Drug
Administration has granted Bronchitol fast track status and it is designated
as an orphan drug in the U.S. and Europe.
Forward-Looking Statements
The statements contained in this media release that are not purely
historical are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements in
this media release include statements regarding our expectations, beliefs,
hopes, goals, intentions, initiatives or strategies, including statements
regarding the potential for Aridol and/or Bronchitol. All forward-looking
statements included in this media release are based upon information available
to us as of the date hereof, and we assume no obligation to update any such
forward-looking statement as a result of new information, future events or
otherwise. We cannot guarantee that any product candidate will receive FDA or
other regulatory approval or that we will seek any such approval. Factors that
could cause or contribute to such differences include, but are not limited to,
factors discussed in the "Risk Factors and Other Uncertainties" section of our
Form 20-F lodged with the U.S. Securities and Exchange Commission.
CONTACT:
Alan Robertson
Chief Executive Officer
Tel: +61-2-9454-7200
Email: alan.robertson@pharmaxis.com.au
Further information on the Program is available from IDIS Limited:
Tel: +44-1932-824000
Email: gma@idispharma.com
Released through:
Australia:
Virginia Nicholls
Tel: +61-417-610-824
Email: virginia.nicholls@pharmaxis.com.au
United States:
Brandon Lewis
Trout Group
Tel: +1-646-378-2915
Email: blewis@troutgroup.com
SOURCE Pharmaxis Ltd
Alan Robertson, Chief Executive Officer of Pharmaxis, +61-2-9454-7200,
alan.robertson@pharmaxis.com.au or IDIS Limited, +44-1932- 824000,
gma@idispharma.com
